Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meliston
- Development stage
- Unknown
- Lead developer
- PharmaSGP
- Administration
- Oral
01
Overview
Meliston is an approved homeopathic medicine developed and marketed by PharmaSGP. It is formulated as oral tablets containing Rhus toxicodendron (also known as Toxicodendron quercifolium) at a D6 dilution (Trit. D6). Meliston is indicated for the treatment of anxiety, restlessness, low mood, and dizziness. As a homeopathic preparation, it is designed to address both mental and physical symptoms of stress and anxiety without the risk of dependency or known drug interactions.
- Brand names
- Meliston
- Other names
- Rhus toxicodendronRhus toxicodendron Trit. D6Toxicodendron quercifoliumToxicodendron quercifolium Trit. D6
Beyond the preview
Go deeper on Meliston.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meliston.